undamentalytics Newsletter
Sign in

Haemonetics Corp cash flow statement

In fiscal 2026, Haemonetics Corp's operations generated $293m of cash; it spent $32.8m on capital projects, leaving free cash flow of $260m. It returned $175m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Apr 20102011Apr 20112012Mar 20122013Mar 20132014Mar 20142015Mar 20152016Apr 20162017Apr 20172018Mar 20182019Mar 20192020Mar 20202021Apr 20212022Apr 20222023Apr 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Cash from operations13112311585140127122160220159158109172273182182293328
Depreciation and amortisation43485065828690908910911084989397116112110
Stock-based pay101191113147913172026242628303434
Capital spending5647536274122102767511949379719138393337
Free cash flow74776223665198414640109727682144142260291
Free cash flow after stock pay6466531253−913741332389465156115113227257
Share buybacks4050505003961010016017500750225175—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: HAE vs STVNHAE vs PENHAE vs MMSI

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Haemonetics Corp's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Haemonetics Corp.